Abatacept Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

• News
• Research
• Blogs
• Alerts
• Clinical Trials

Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Calcineurin Inhibitor at Patients With Hemoblastosis
Conditions:   Acute Lymphoblastic Leukemia;   Myeloblastic Leukemia;   Biphenotypic Acute Leukemia;   Malignant Lymphoma;   Myelodysplastic Syndromes;   Juvenile Myelomonocytic Leukemia Intervention:   Combination Product: GVHD prevention: post-transplantation cyclophosphamide, abatacept, vedolizumab, calcineurin inhibitor Sponsor:   Federal Research Institute of Pediatric Hematology, Oncology and Immunology Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 25, 2022 Category: Research Source Type: clinical trials